Newland Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	697.81	662.81	720.99	643.85	621.21	508.93
Other Revenue	12.73	9.57	5.44	7.59	6.15	4.91
Revenue	710.55	672.38	726.44	651.44	627.36	513.84
Revenue Growth	3.20%	-7.44%	11.51%	3.84%	22.09%	18.63%
Cost of Revenue	507.61	447.24	437.43	392.84	404.01	307.82
Gross Profit	202.94	225.14	289	258.6	223.36	206.02
Selling, General & Admin	58.42	55.91	47.62	44.49	38.83	31.56
Research & Development	34.01	46.18	55.49	51.96	30	20.59
Other Operating Expenses	7.35	4.43	2.71	3.89	6.99	6.4
Operating Expenses	103.18	105.66	108.1	96.75	78.04	69.69
Operating Income	99.76	119.49	180.91	161.85	145.31	136.33
Interest Expense	-0.16	-0.21	-0.09	-0.13	-6.88	-6.71
Interest & Investment Income	9.5	10.94	16.7	19.63	1.34	0.26
Currency Exchange Gain (Loss)	-0.14	-0.03	0.25	0.06	0.29	-0.13
Other Non Operating Income (Expenses)	-0.06	-0.02	-0.06	-0.12	-0.09	-0.06
EBT Excluding Unusual Items	108.9	130.16	197.7	181.29	139.97	129.69
Gain (Loss) on Sale of Investments	0.58	0.19	-0.23	0.04	1.36	0.17
Gain (Loss) on Sale of Assets	0.61	-	-	0.07	-0.44	-0.21
Asset Writedown	-1.55	-1.49	-2.62	-1.46	-0.32	-0.11
Other Unusual Items	7.23	5.26	2.5	1.22	2.31	2.4
Pretax Income	115.77	134.12	197.35	181.16	142.88	131.94
Income Tax Expense	13.56	14.06	24.34	23.96	11.17	17.11
Earnings From Continuing Operations	102.21	120.07	173.01	157.2	131.71	114.82
Minority Interest in Earnings	1.77	1.18	0.62	1.78	0.6	0.15
Net Income	103.98	121.25	173.63	158.98	132.3	114.98
Net Income to Common	103.98	121.25	173.63	158.98	132.3	114.98
Net Income Growth	-25.81%	-30.17%	9.21%	20.16%	15.07%	-2.94%
Shares Outstanding (Basic)	391	391	395	391	302	294
Shares Outstanding (Diluted)	391	391	395	391	302	294
Shares Change	-0.13%	-0.88%	1.05%	29.52%	2.59%	0.64%
EPS (Basic)	0.27	0.31	0.44	0.41	0.44	0.39
EPS (Diluted)	0.27	0.31	0.44	0.41	0.44	0.39
EPS Growth	-25.72%	-29.54%	8.08%	-7.22%	12.17%	-3.36%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Free Cash Flow	41.12	15.55	15.97	162.94	8.5	23.68
Free Cash Flow Per Share	0.10	0.04	0.04	0.42	0.03	0.08
Dividend Per Share	0.200	0.200	0.400	0.204	0.170	-
Dividend Growth	-50.00%	-50.00%	95.98%	19.99%	-	-
Gross Margin	28.56%	33.48%	39.78%	39.70%	35.60%	40.09%
Operating Margin	14.04%	17.77%	24.90%	24.85%	23.16%	26.53%
Profit Margin	14.63%	18.03%	23.90%	24.40%	21.09%	22.38%
Free Cash Flow Margin	5.79%	2.31%	2.20%	25.01%	1.35%	4.61%
EBITDA	159.86	172.06	216.31	190.69	167.38	157.19
EBITDA Margin	22.50%	25.59%	29.78%	29.27%	26.68%	30.59%
D&A For EBITDA	60.11	52.57	35.4	28.84	22.06	20.86
EBIT	99.76	119.49	180.91	161.85	145.31	136.33
EBIT Margin	14.04%	17.77%	24.90%	24.85%	23.16%	26.53%
Effective Tax Rate	11.71%	10.48%	12.33%	13.23%	7.82%	12.97%
Revenue as Reported	710.55	672.38	726.44	651.44	627.36	513.84
Advertising Expenses	-	1.1	0.85	0.51	0.2	0.28